nach oben

Current Treatment Options in Pediatrics

Erschienen in:

01.06.2019 | Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Chronic Kidney Disease: Treatment of Comorbidities I (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease)

verfasst von: Amy J. Kogon, MD, Lyndsay A. Harshman, MD

Erschienen in: Current Treatment Options in Pediatrics | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This review discusses the complications of nutrition, growth, neurocognitive function, and mineral and bone disorder in pediatric chronic kidney disease. We discuss the most recent evidence-based methods for evaluation and prevention of these complications in addition to treatment strategies to address the complications and mitigate adverse effects.

Recent findings

Frequent nutritional assessment is important, particularly for infants and young children. Due to anorexia, oral aversion, and dietary restrictions, weight gain may be difficult to achieve. Adequate nutrition is important for growth. Children with CKD tend to be short, which can impact quality of life and social achievements. Once nutrition is optimized, growth hormone is an effective, but underutilized strategy to improving terminal height. Mineral and bone disorder is a difficult but common complication of CKD which may present with and be driven by abnormalities in calcium, phosphorus, and parathyroid hormone levels. Treatment strategies include dietary phosphorus restriction, phosphorus binders, and inactive vitamin D and active vitamin D sterols. Effective treatment may reduce the risk for bone deformities, growth abnormalities, fractures, cardiovascular disease, and mortality. Children with CKD also suffer from cognitive difficulties. Control of anemia, aggressive childhood nutrition, and decreased exposure to heavy metals (via dialysate and dietary binding agents) has provided substantial improvement to the more profound neurocognitive sequelae observed prior to the 1990s. Current prevention of cognitive sequelae may best be directed at improved blood pressure control and augmented school support.

Summary

Pediatric CKD has systemic ramifications and can impact all aspects of normal development, including nutrition, growth, bone and mineral metabolism, and neurocognitive function. Regular evaluation for disease complications and prompt treatment can reduce the untoward effects of CKD thereby improving the quality and duration of life.

National Kidney Fountation. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Am J Kidney Dis. 2009;53(3):S1–123.

• Ayestaran FW, Schneider MF, Kaskel FJ, Srivaths PR, Seo-Mayer PW, Moxey-Mims M, et al. Perceived appetite and clinical outcomes in children with chronic kidney disease. Pediatr Nephrol. 2016;31(7):1121–7. https://doi.org/10.1007/s00467-016-3321-9 This paper utilized data from the Chronic Kidney Disease in Children (CKiD) study and highlights the importance of self-reported appetite in the pediatric CKD population. Lower appetite is directly related to diminishing renal function and poorer clinical outcomes, including more hospitalizations and lower quality of life.

Warady BA, Kriley M, Belden B, Hellerstein S, Alan U. Nutritional and behavioral-aspects of nasogastric tube-feeding in infants receiving chronic peritoneal-dialysis. Adv Perit D. 1990;6:265–8.

Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest. 2005;115(6:1659–65. https://doi.org/10.1172/JCI22521.CrossRef

Rodriguez Ayala E, Pecoits-Filho R, Heimburger O, Lindholm B, Nordfors L, Stenvinkel P. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant. 2004;19(2):421–6.CrossRefPubMed

Foreman JW, Abitbol CL, Trachtman H, Garin EH, Feld LG, Strife CF, et al. Nutritional intake in children with renal insufficiency: a report of the growth failure in children with renal diseases study. J Am Coll Nutr. 1996;15(6):579–85.CrossRefPubMed

Rees L, Mak RH. Nutrition and growth in children with chronic kidney disease. Nat Rev Nephrol. 2011;7(11):615–23. https://doi.org/10.1038/nrneph.2011.137.CrossRefPubMed

Rees L, Jones H. Nutritional management and growth in children with chronic kidney disease. Pediatr Nephrol. 2013;28(4):527–36. https://doi.org/10.1007/s00467-012-2258-x.CrossRefPubMed

Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet. 1997;349(9059):1117–23.CrossRefPubMed

10.

Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, et al. Effect of dietary protein restriction on nutritional status in the modification of diet in renal disease study. Kidney Int. 1997;52(3):778–91.CrossRefPubMed

11.

Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev. 2007;4:CD006863. https://doi.org/10.1002/14651858.CD006863.CrossRef

12.

Rees L, Shaw V. Nutrition in children with CRF and on dialysis. Pediatr Nephrol. 2007;22(10):1689–702. https://doi.org/10.1007/s00467-006-0279-z.CrossRefPubMedPubMedCentral

13.

Parekh RS, Flynn JT, Smoyer WE, Milne JL, Kershaw DB, Bunchman TE, et al. Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy. J Am Soc Nephrol. 2001;12(11):2418–26.PubMed

14.

Wassner SJ. The effect of sodium repletion on growth and protein turnover in sodium-depleted rats. Pediatr Nephrol. 1991;5(4):501–4.CrossRefPubMed

15.

Kiepe D, Tonshoff B. Insulin-like growth factors in normal and diseased kidney. Endocrinol Metab Clin N Am. 2012;41(2):351–74vii. https://doi.org/10.1016/j.ecl.2012.04.015.CrossRef

16.

Maniar S, Kleinknecht C, Zhou X, Motel V, Yvert JP, Dechaux M. Growth hormone action is blunted by acidosis in experimental uremia or acid load. Clin Nephrol. 1996;46(1):72–6.PubMed

17.

Rodig NM, McDermott KC, Schneider MF, Hotchkiss HM, Yadin O, Seikaly MG, et al. Growth in children with chronic kidney disease: a report from the chronic kidney disease in children study. Pediatr Nephrol. 2014;29(10):1987–95. https://doi.org/10.1007/s00467-014-2812-9.CrossRefPubMedPubMedCentral

18.

Mitch WE. Influence of metabolic acidosis on nutrition. Am J Kidney Dis. 1997;29(5):R46–R8. https://doi.org/10.1016/S0272-6386(97)90115-3.CrossRef

19.

de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9):2075–84. https://doi.org/10.1681/Asn.2008111205.CrossRefPubMedPubMedCentral

20.

Kausman JY, Powell HR, Jones CL. Anemia in pediatric renal transplant recipients. Pediatr Nephrol. 2004;19(5):526–30. https://doi.org/10.1007/s00467-004-1427-y.CrossRefPubMed

21.

Boehm M, Riesenhuber A, Winkelmayer WC, Arbeiter K, Mueller T, Aufricht C. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol. 2007;22(8):1189–93. https://doi.org/10.1007/s00467-007-0472-8.CrossRefPubMed

22.

Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L. Outcome and growth of infants with severe chronic renal failure. Kidney Int. 2000;57(4):1681–7. https://doi.org/10.1046/j.1523-1755.2000.00013.x.CrossRefPubMed

23.

Nissel R, Brazda I, Feneberg R, Wigger M, Greiner C, Querfeld U, et al. Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int. 2004;66(2):792–800. https://doi.org/10.1111/j.1523-1755.2004.00805.x.CrossRefPubMed

24.

North American Pediatric Renal Transplant Cooperative Study Annual Report. 2014. https://web.emmes.com/study/ped/annlrept/annualrept2014.pdf. Accessed 25 Jan 2019

25.

Nissel R, Lindberg A, Mehls O, Haffner D, Pfizer international growth database international B. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab. 2008;93(4):1359–65. https://doi.org/10.1210/jc.2007-2302.CrossRefPubMed

26.

Fine RN, Ho M, Tejani A, North American Pediatric Renal Trasplant Cooperative S. The contribution of renal transplantation to final adult height: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Pediatr Nephrol. 2001;16(12):951–6. https://doi.org/10.1007/s004670100002. CrossRefPubMed

27.

Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics. 2010;125(2):e349–57. https://doi.org/10.1542/peds.2009-0085.CrossRefPubMed

28.

Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, et al. Long-term social outcome of children after kidney transplantation. Transplantation. 2004;77(7):1033–7.CrossRefPubMed

29.

Al-Uzri A, Matheson M, Gipson DS, Mendley SR, Hooper SR, Yadin O, et al. The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr. 2013;163(3):736–41 e1. https://doi.org/10.1016/j.jpeds.2013.03.016.CrossRefPubMedPubMedCentral

30.

Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German study Group for Growth Hormone Treatment in chronic renal failure. N Engl J Med. 2000;343(13):923–30. https://doi.org/10.1056/NEJM200009283431304.CrossRefPubMed

31.

Mehls O, Lindberg A, Nissel R, Haffner D, Hokken-Koelega A, Ranke MB. Predicting the response to growth hormone treatment in short children with chronic kidney disease. J Clin Endocrinol Metab. 2010;95(2):686–92. https://doi.org/10.1210/jc.2009-1114.CrossRefPubMed

32.

Akchurin OM, Kogon AJ, Kumar J, Sethna CB, Hammad HT, Christos PJ, et al. Approach to growth hormone therapy in children with chronic kidney disease varies across North America: the Midwest Pediatric Nephrology Consortium report. BMC Nephrol. 2017;18(1):181. https://doi.org/10.1186/s12882-017-0599-1.CrossRefPubMedPubMedCentral

33.

Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016;27(2):543–50. https://doi.org/10.1681/ASN.2015020152.CrossRefPubMed

34.

•• Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36. https://doi.org/10.1016/j.kint.2017.04.006 The KDIGO 2017 Clinical Practice Guideline Update is a selective update to the 2009 KDIGO mineral bone disease guidelines. The guidelines are adult- and pediatric-specific and cover the spectrum of non-dialysis CKD to transplant. Pertinent to this update is the diagnosis of bone abnormalities and treatment of CKD-MBD by phosphate lowering and calcium maintenance.

35.

Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9(2):344–53. https://doi.org/10.2215/CJN.05840513.CrossRefPubMed

36.

Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 2013;83(1):160–6. https://doi.org/10.1038/ki.2012.327.CrossRefPubMed

37.

Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52. https://doi.org/10.1161/CIRCULATIONAHA.108.844506.CrossRefPubMedPubMedCentral

38.

Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92. https://doi.org/10.1056/NEJMoa0706130.CrossRefPubMedPubMedCentral

39.

Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol. 2012;27(11):2129–36. https://doi.org/10.1007/s00467-012-2224-7.CrossRefPubMed

40.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–56. https://doi.org/10.1056/NEJMoa022536.CrossRefPubMed

41.

Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013;83(5):959–66. https://doi.org/10.1038/ki.2012.403.CrossRefPubMed

42.

Kumar J, McDermott K, Abraham AG, Friedman LA, Johnson VL, Kaskel FJ, et al. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the chronic kidney disease in children (CKiD) cohort. Pediatr Nephrol. 2016;31(1):121–9. https://doi.org/10.1007/s00467-015-3190-7.CrossRefPubMed

43.

Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268–77. https://doi.org/10.1016/S0140-6736(13)60897-1.CrossRefPubMed

44.

Cozzolino M, Gallieni M, Brancaccio D. The mechanisms of hyperphosphatemia-induced vascular calcification. Int J Artif Organs. 2008;31(12):1002–3.CrossRefPubMed

45.

Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol. 2010;25(4):769–78. https://doi.org/10.1007/s00467-009-1337-0.CrossRefPubMed

46.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.CrossRefPubMed

47.

Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8. https://doi.org/10.1681/ASN.2004070602.CrossRefPubMed

48.

Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30. https://doi.org/10.1053/j.ajkd.2008.03.020.CrossRefPubMed

49.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53. https://doi.org/10.1038/sj.ki.5000414.CrossRefPubMed

50.

Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010;5(10):1860–6. https://doi.org/10.2215/CJN.01330210.CrossRefPubMedPubMedCentral

51.

Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(1):146–52. https://doi.org/10.2215/CJN.05940611.CrossRefPubMed

52.

Duquette PJ, Hooper SR, Wetherington CE, Icard PF, Gipson DS. Brief report: intellectual and academic functioning in pediatric chronic kidney disease. J Pediatr Psychol. 2007;32(8):1011–7. https://doi.org/10.1093/jpepsy/jsm036.CrossRefPubMed

53.

Hooper SR, Gerson AC, Butler RW, Gipson DS, Mendley SR, Lande MB, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(8):1824–30. https://doi.org/10.2215/CJN.09751110.CrossRefPubMedPubMedCentral

54.

Mendley SR, Matheson MB, Shinnar S, Lande MB, Gerson AC, Butler RW, et al. Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int. 2015;87(4):800–6. https://doi.org/10.1038/ki.2014.323.CrossRefPubMed

55.

Lande MB, Mendley SR, Matheson MB, Shinnar S, Gerson AC, Samuels JA, et al. Association of blood pressure variability and neurocognition in children with chronic kidney disease. Pediatr Nephrol. 2016;31(11):2137–44. https://doi.org/10.1007/s00467-016-3425-2.CrossRefPubMedPubMedCentral

56.

Gipson DS, Hooper SR, Duquette PJ, Wetherington CE, Stellwagen KK, Jenkins TL, et al. Memory and executive functions in pediatric chronic kidney disease. Child Neuropsychol. 2006;12(6):391–405. https://doi.org/10.1080/09297040600876311.CrossRefPubMed

57.

Ruebner RL, Laney N, Kim JY, Hartung EA, Hooper SR, Radcliffe J, et al. Neurocognitive dysfunction in children, adolescents, and young adults with CKD. Am J Kidney Dis. 2016;67(4):567–75. https://doi.org/10.1053/j.ajkd.2015.08.025. CrossRefPubMed

58.

Harshman LA, Johnson RJ, Matheson MB, Kogon AJ, Shinnar S, Gerson AC, et al. Academic achievement in children with chronic kidney disease: a report from the CKiD cohort. Pediatr Nephrol. 2018;34:689–96. https://doi.org/10.1007/s00467-018-4144-7.CrossRefPubMedPubMedCentral

59.

Qvist E, Pihko H, Fagerudd P, Valanne L, Lamminranta S, Karikoski J, et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant. 2002;6(1):53–62.CrossRefPubMed

60.

Warady BA, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating peritoneal dialysis in early infancy. Pediatr Nephrol. 1999;13(9):759–65. https://doi.org/10.1007/s004670050694.CrossRefPubMed

61.

• Hooper SR, Gerson AC, Johnson RJ, Mendley SR, Shinnar S, Lande MB, et al. Neurocognitive, social-behavioral, and adaptive functioning in preschool children with mild to moderate kidney disease. J Dev Behav Pediatr. 2016;37(3):231–8. https://doi.org/10.1097/DBP.0000000000000267 The impact of CKD in early development has been widely documented in advanced CKD/ESRD. This paper utilized data from the Chronic Kidney Disease in Children (CKiD) study to detail neurocognitive outcomes for pediatric patients with more mild to moderate CKD. Findings suggest relatively intact functioning for preschool children. Higher eGFR and lack of anemia were associated with more intact developmental level/IQ.

62.

Hooper SR, Duquette PJ, Icard P, Wetherington CE, Harrell W, Gipson DS. Social-behavioural functioning in paediatric chronic kidney disease. Child Care Health Dev. 2009;35(6):832–40. https://doi.org/10.1111/j.1365-2214.2009.00992.x.CrossRefPubMed

63.

Lande MB, Gerson AC, Hooper SR, Cox C, Matheson M, Mendley SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. Clin J Am Soc Nephrol. 2011;6(8):1831–7. https://doi.org/10.2215/CJN.00810111.CrossRefPubMedPubMedCentral

Titel: Chronic Kidney Disease: Treatment of Comorbidities I (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease)
verfasst von: Amy J. Kogon, MD
Lyndsay A. Harshman, MD
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Current Treatment Options in Pediatrics / Ausgabe 2/2019
Elektronische ISSN: 2198-6088
DOI: https://doi.org/10.1007/s40746-019-00152-9

Gastrointestinal Dysmotility and the Implications for Respiratory Disease

Pulmonary (RP Boesch, Section Editor)

Improving Safety in Health Care: Beyond Standard Hospital-Acquired Conditions

Patient Safety (M Scanlon, Section Editor)

Patient Safety: What Is Working and Why?

Patient Safety (M Scanlon, Section Editor)

Accelerating Improvement in Children’s Healthcare Through Quality Improvement Collaboratives: a Synthesis of Recent Efforts

Patient Safety (M Scanlon, Section Editor)

Resilience Engineering, Safety, and Implications for Pediatric Care

Patient Safety (M Scanlon, Section Editor)

Safety in Children With Medical Complexity: Our Canaries in the Coal Mine?

Patient Safety (M Scanlon, Section Editor)

Neu im Fachgebiet Pädiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

09.01.2025
Gestationsdiabetes
Nachrichten

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen.

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

09.01.2025
Multiple Sklerose
Nachrichten

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

07.01.2025
Harnwegsinfektionen in der Pädiatrie
Nachrichten

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Chronic Kidney Disease: Treatment of Comorbidities I (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease)